Technical Analysis for ALDX - Aldeyra Therapeutics, Inc.

Grade Last Price % Change Price Change
F 2.78 -0.36% -0.01
ALDX closed down 0.36 percent on Monday, March 18, 2024, on 66 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -0.36%
Pocket Pivot Bullish Swing Setup -0.36%
NR7 Range Contraction -0.36%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 15 hours ago
1.5x Volume Pace about 19 hours ago
Down 1% about 19 hours ago
Rose Above Previous Day's High about 20 hours ago
Up 2% about 20 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aldeyra Therapeutics, Inc. (Aldeyra) is a biotechnology company. The Company is focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The Company is developing NS2. NS2 is a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of diseases, which include Sjogren-Larsson Syndrome (SLS), discoid lupus, acute anterior uveitis and ocular rosacea with meibomian gland dysfunction. Aldeyra is also developing aldehyde traps distinct from NS2. As of April 7, 2014, it had evaluated NS2 in a Phase I clinical trial in 48 volunteers.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Disease Organ Systems Autoimmune Disease Rare Diseases Dysfunction Lupus Syndromes Uveitis Inflammatory Rosacea Systemic Lupus Erythematosus Discoid Lupus Meibomian Gland Ns2

Is ALDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.97
52 Week Low 1.42
Average Volume 506,912
200-Day Moving Average 5.21
50-Day Moving Average 3.33
20-Day Moving Average 3.48
10-Day Moving Average 3.28
Average True Range 0.23
RSI (14) 33.77
ADX 25.33
+DI 17.98
-DI 34.38
Chandelier Exit (Long, 3 ATRs) 3.66
Chandelier Exit (Short, 3 ATRs) 3.39
Upper Bollinger Bands 4.35
Lower Bollinger Band 2.62
Percent B (%b) 0.09
BandWidth 49.63
MACD Line -0.14
MACD Signal Line -0.01
MACD Histogram -0.136
Fundamentals Value
Market Cap 163.53 Million
Num Shares 58.8 Million
EPS -0.78
Price-to-Earnings (P/E) Ratio -3.56
Price-to-Sales 0.00
Price-to-Book 1.58
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.94
Resistance 3 (R3) 2.95 2.90 2.91
Resistance 2 (R2) 2.90 2.86 2.90 2.90
Resistance 1 (R1) 2.84 2.84 2.82 2.83 2.89
Pivot Point 2.80 2.80 2.79 2.79 2.80
Support 1 (S1) 2.74 2.76 2.72 2.73 2.67
Support 2 (S2) 2.69 2.73 2.69 2.66
Support 3 (S3) 2.63 2.69 2.65
Support 4 (S4) 2.62